

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Perindopril erbumine

September 9, 2025

Therapeutic category

Antihypertensives

Non-proprietary name

Perindopril erbumine

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision
<p>11. ADVERSE REACTIONS</p> <p>11.1 Clinically Significant Adverse Reactions</p> <p>Angioedema</p> <p>Angioedema accompanied by dyspnoea, with swelling of the face, tongue, glottis, and larynx, may occur. In such cases, administration should be discontinued immediately, and appropriate measures should be taken, such as administering adrenaline injections and maintaining the airway.</p>	<p>11. ADVERSE REACTIONS</p> <p>11.1 Clinically Significant Adverse Reactions</p> <p>Angioedema</p> <p>Angioedema accompanied by dyspnoea, with swelling of the face, tongue, glottis, and larynx, may occur. In such cases, administration should be discontinued immediately, and appropriate measures should be taken, such as administering adrenaline injections and maintaining the airway. <u>Of note, intestinal angioedema accompanied by abdominal pain, queasy, vomiting, diarrhoea, etc. may occur.</u></p>